Asset Details
Do you wish to reserve the book?
Long-Term Firocoxib Use in Horses
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Firocoxib Use in Horses
Do you wish to request the book?
Long-Term Firocoxib Use in Horses
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Firocoxib Use in Horses
2025
Overview
Abstract
Background
Many horses receive firocoxib over multiple years, and studies evaluating hematologic and biochemical values in these animals are lacking.
Objective
To describe the hematologic and biochemical values of horses receiving long-term firocoxib.
Animals
A total of 79 horses receiving long-term firocoxib and 153 horses not receiving long-term firocoxib and not presenting for a specific medical problem.
Methods
Retrospective study comparing horses receiving firocoxib (F group) and no firocoxib (NF group). Signalment, hematologic, and biochemical values were compared between the two groups. Simple linear regression was used to evaluate the relationship between the duration of firocoxib administration and specific laboratory variables.
Results
Horses receiving long-term firocoxib (F) were 19 (5–33) years as compared to 15 (1–33) years for the NF group (p < 0.0001). The most common reason for receiving firocoxib was osteoarthritis in 44/79 (56%) of the animals in the F group. Horses in the F group had a total protein concentration of 6.6 (5.8–8.0) g/dL as compared to 6.5 (5.1–8) g/dL in the NF group (p = 0.03). The sodium concentration for F horses was 139 (133–143) mmol/L as compared to 138 (129–145) mmol/L for NF horses (p = 0.01). Total white blood cell count was 6.11 (2.82–14.36) 103 cells/uL in the F group as compared to 6.46 (3.04–14.71) 103 cells/uL in the NF group (p = 0.03). None of the laboratory variables were associated with the duration of firocoxib administration.
Conclusions and Clinical Importance
Many horses receive firocoxib for multiple years, and equine practitioners should be aware that expected changes in laboratory values are minimal.
Publisher
Oxford University Press,John Wiley & Sons, Inc,Wiley
Subject
4-Butyrolactone - administration & dosage
/ 4-Butyrolactone - adverse effects
/ 4-Butyrolactone - analogs & derivatives
/ 4-Butyrolactone - therapeutic use
/ Animals
/ Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
/ Anti-Inflammatory Agents, Non-Steroidal - adverse effects
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Female
/ Horse Diseases - drug therapy
/ Horses
/ lameness
/ Male
/ NSAID
/ Osteoarthritis - drug therapy
/ Proteins
/ renal
/ Sodium
/ Software
/ Sulfones - administration & dosage
/ surgery
